Published On:November 25, 2016, 2:58 pm
Next generation sequencing (NGS) is also termed as high-throughput sequencing; it facilitates scientists to ascertain a procedure wherein they sequence and assemble billions of shorts DNA strands. It is done to identify the accurate order of nucleotides within a DNA molecule. The innovation of next generation sequencing technologies has contributed considerable alterations in the entire sequencing procedure by rendering high throughput, flexibility, speed and reduced sequencing cost over thousand folds. NGS has several latest sequencing technologies such as Roche 454 sequencing and Illumina sequencing. In just a solo sequencing run, NGS has the ability to develop hundreds of giga-bases of nucleotide sequence data. NGS offers services in the R&D field such as metagenomics, cancer research, newborn sequencing and genetic disease research. Cut-down in the cost of reduction has resulted in the expansion of the use of next generation sequencing in an array of clinical applications. A few of the next generation sequencing applications are discovery of transcriptional factor binding sites, non-coding RNA expression profiling, Whole-genome sequencing, and targeted re-sequencing. Next generation sequencing is used in many fields such as agriculture research, personalized medicines, biological drug discovery and animal research.
To Request Sample Copy of This Report: http://www.qyresearchgroups.com/request-sample/166774
The global Next generation sequencing (NGS) market was valued at US $4,031.7 million in 2016, and is predicted to approximately reach US $10,371.1 million by the end of 2021, while growing at a CAGR of 20.8%. Some of the key market drivers of the NGS market are technological enhancements in NGS products, advent of new market players, increase in applications of NGS, escalating partnerships & collaborations among market players, and increased prevalence of cancer which transmitted pre- and neo-natal disorders and rare disorders. Furthermore, increased adoption amongst the researchers and customers, and replacing microarray technology by MGS, and cost efficiency of the sequencing are some of the reasons accounting for the higher market growth during the forecast period. Nevertheless, problem with maintaining greater accuracy and standardization, insufficiency of skilled labor and data analysis, dependency of researchers on grants, are a few market restraints of this industry. The market potential of NGS market is dynamic, holding a wide range applications is different fields of biological research, drug discovery, personalized medicine, and diagnostics.
Geographically, North America was responsible for maximum market share in 2014 which was followed by Europe owing to the increased support from the government towards R&D. Asia Pacific region is predicted to account highest growth during the forecast period due to the saturation in the market of the developed regions. Moreover, technological enhancement, escalating drug delivery initiatives by all the healthcare companies, greater capital investment by biotechnology and pharmaceutical companies, are a few reasons which is anticipated to drive the market of the Asia Pacific region. Some of the major market players of the global Next Generation Sequencing (NGS) market are Illumina, Inc., Qiagen N.V., QuantuMDx Group, Quest Diagnostics, RainDance Technologies, Inc., Response Genetics, Inc., Roche, SeqLL, LLC, Sequenta, Inc., Mayo Medical Laboratories and Mayo Clinic, MolecularMD Corporation, Multiplicom NV, DNA Electronics Ltd., DNASTAR, Inc., and Innovations Exchange Pte Ltd (INEX).
We will be happy to help you find what you need. Please write to us: